{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T07:18:28Z","timestamp":1794467908582,"version":"4.9.1"},"reference-count":23,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T00:00:00Z","timestamp":1748476800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["INV-007217"],"award-info":[{"award-number":["INV-007217"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["INV-008924"],"award-info":[{"award-number":["INV-008924"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["INV-042281"],"award-info":[{"award-number":["INV-042281"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>RTS,S\/AS01 vaccine efficacy (VE) was previously shown as lower in African adults than in malaria-naive US adults, potentially due to concurrent Plasmodium falciparum infections. We investigated whether treatment of infection prior to vaccination would lead to improved VE and immunogenicity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A phase 2b study in Kenyan adults evaluated the efficacy of RTS,S\/AS01E in conjunction with antimalarial chemopreventive drugs. Participants, grouped by baseline presence or absence of P. falciparum infections, were randomized to receive RTS,S\/AS01E or rabies vaccine. Four groups received antimalarial drugs prior to immunization and were followed for 6 months to assess P. falciparum infection. We included an additional group not treated with antimalarial drugs for immunological assessment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>VE (RTS,S\/AS01E vs rabies vaccine) was 34.8% (95% confidence interval [CI], 8.9% to 53.4%) and \u221224.0% (95% CI, \u221297% to 22.4%) in baseline P. falciparum-positive and P. falciparum-negative participants, respectively. In RTS,S\/AS01E recipients, there were no statistical differences in anticircumsporozoite (anti-CS) antibody titers in baseline P. falciparum-positive or P. falciparum-negative participants, or in susceptibility to infection during the postvaccination follow-up period. Drug treatment did not improve anti-CS antibody titers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Treating P. falciparum infections during vaccination does not result in increased VE. Anti-CS antibody responses to vaccination do not differ with baseline P. falciparum infection status, drug treatment, or susceptibility to P. falciparum infections.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical Trials Registration<\/jats:title>\n                    <jats:p>NCT04661579; PACTR202006896481432.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/infdis\/jiaf274","type":"journal-article","created":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T09:40:15Z","timestamp":1747993215000},"page":"e372-e382","source":"Crossref","is-referenced-by-count":4,"title":["Efficacy of RTS,S\/AS01E Only Seen in Baseline Parasitemic and Not Baseline Aparasitemic\n                    <i>Plasmodium falciparum<\/i>\n                    -Exposed, Drug-Treated Kenyan Adults"],"prefix":"10.1093","volume":"232","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1504-253X","authenticated-orcid":false,"given":"Nathanial K","family":"Copeland","sequence":"first","affiliation":[{"name":"Kombewa Clinical Research Centre, Kenya Medical Research Institute\/US Army Medical Research Directorate-Africa , Kisumu ,","place":["Kenya"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucas","family":"Otieno","sequence":"additional","affiliation":[{"name":"Kombewa Clinical Research Centre, Kenya Medical Research Institute\/US Army Medical Research Directorate-Africa , Kisumu ,","place":["Kenya"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"June Doryne","family":"Otieno","sequence":"additional","affiliation":[{"name":"Kombewa Clinical Research Centre, Kenya Medical Research Institute\/US Army Medical Research Directorate-Africa , Kisumu ,","place":["Kenya"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Solomon","family":"Otieno","sequence":"additional","affiliation":[{"name":"Kombewa Clinical Research Centre, Kenya Medical Research Institute\/US Army Medical Research Directorate-Africa , Kisumu ,","place":["Kenya"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salome","family":"Chira","sequence":"additional","affiliation":[{"name":"Center for Vaccine Innovation and Access, PATH , Washington, District of Columbia , ; Seattle, Washington, USA; Nairobi, Kenya; and Geneva, Switzerland","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Ivinson","sequence":"additional","affiliation":[{"name":"Center for Vaccine Innovation and Access, PATH , Washington, District of Columbia , ; Seattle, Washington, USA; Nairobi, Kenya; and Geneva, Switzerland","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Onyango","sequence":"additional","affiliation":[{"name":"Kombewa Clinical Research Centre, Kenya Medical Research Institute\/US Army Medical Research Directorate-Africa , Kisumu ,","place":["Kenya"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"Wasuna","sequence":"additional","affiliation":[{"name":"Kombewa Clinical Research Centre, Kenya Medical Research Institute\/US Army Medical Research Directorate-Africa , Kisumu ,","place":["Kenya"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hoseah","family":"Akala","sequence":"additional","affiliation":[{"name":"Kombewa Clinical Research Centre, Kenya Medical Research Institute\/US Army Medical Research Directorate-Africa , Kisumu ,","place":["Kenya"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amos","family":"Onditi","sequence":"additional","affiliation":[{"name":"Kombewa Clinical Research Centre, Kenya Medical Research Institute\/US Army Medical Research Directorate-Africa , Kisumu ,","place":["Kenya"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Sifuna","sequence":"additional","affiliation":[{"name":"Kombewa Clinical Research Centre, Kenya Medical Research Institute\/US Army Medical Research Directorate-Africa , Kisumu ,","place":["Kenya"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8678-7478","authenticated-orcid":false,"given":"Ben","family":"Andagalu","sequence":"additional","affiliation":[{"name":"Kombewa Clinical Research Centre, Kenya Medical Research Institute\/US Army Medical Research Directorate-Africa , Kisumu ,","place":["Kenya"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roselyne","family":"Oyugi","sequence":"additional","affiliation":[{"name":"Kombewa Clinical Research Centre, Kenya Medical Research Institute\/US Army Medical Research Directorate-Africa , Kisumu ,","place":["Kenya"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Omondi","sequence":"additional","affiliation":[{"name":"Kombewa Clinical Research Centre, Kenya Medical Research Institute\/US Army Medical Research Directorate-Africa , Kisumu ,","place":["Kenya"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stellah","family":"Amoit","sequence":"additional","affiliation":[{"name":"Kombewa Clinical Research Centre, Kenya Medical Research Institute\/US Army Medical Research Directorate-Africa , Kisumu ,","place":["Kenya"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1944-8473","authenticated-orcid":false,"given":"Emily","family":"Locke","sequence":"additional","affiliation":[{"name":"Center for Vaccine Innovation and Access, PATH , Washington, District of Columbia , ; Seattle, Washington, USA; Nairobi, Kenya; and Geneva, Switzerland","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Gregory","sequence":"additional","affiliation":[{"name":"Center for Vaccine Innovation and Access, PATH , Washington, District of Columbia , ; Seattle, Washington, USA; Nairobi, Kenya; and Geneva, Switzerland","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8571-8956","authenticated-orcid":false,"given":"Elke S","family":"Bergmann-Leitner","sequence":"additional","affiliation":[{"name":"Biologics Research & Development, Walter Reed Army Institute of Research , Silver Spring, Maryland ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hema","family":"Pindolia","sequence":"additional","affiliation":[{"name":"Human Immunology Laboratory, International AIDS Vaccine Initiative , London ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8396-6748","authenticated-orcid":false,"given":"Mike","family":"Raine","sequence":"additional","affiliation":[{"name":"Center for Vaccine Innovation and Access, PATH , Washington, District of Columbia , ; Seattle, Washington, USA; Nairobi, Kenya; and Geneva, Switzerland","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4216-679X","authenticated-orcid":false,"given":"Chris","family":"Gast","sequence":"additional","affiliation":[{"name":"Center for Vaccine Innovation and Access, PATH , Washington, District of Columbia , ; Seattle, Washington, USA; Nairobi, Kenya; and Geneva, Switzerland","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laina D","family":"Mercer","sequence":"additional","affiliation":[{"name":"Center for Vaccine Innovation and Access, PATH , Washington, District of Columbia , ; Seattle, Washington, USA; Nairobi, Kenya; and Geneva, Switzerland","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3014-3673","authenticated-orcid":false,"given":"John J","family":"Aponte","sequence":"additional","affiliation":[{"name":"Center for Vaccine Innovation and Access, PATH , Washington, District of Columbia , ; Seattle, Washington, USA; Nairobi, Kenya; and Geneva, Switzerland","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Lievens","sequence":"additional","affiliation":[{"name":"Vaccine Clinical R&D, GlaxoSmithKline , Wavre ,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian F","family":"Ockenhouse","sequence":"additional","affiliation":[{"name":"Center for Vaccine Innovation and Access, PATH , Washington, District of Columbia , ; Seattle, Washington, USA; Nairobi, Kenya; and Geneva, Switzerland","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia K","family":"Lee","sequence":"additional","affiliation":[{"name":"Center for Vaccine Innovation and Access, PATH , Washington, District of Columbia , ; Seattle, Washington, USA; Nairobi, Kenya; and Geneva, Switzerland","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,5,29]]},"reference":[{"key":"2025092306181873600_jiaf274-B1","author":"World Health Organization"},{"key":"2025092306181873600_jiaf274-B2","author":"World Health Organization"},{"key":"2025092306181873600_jiaf274-B3","doi-asserted-by":"crossref","first-page":"e0131571","DOI":"10.1371\/journal.pone.0131571","article-title":"Ad35.CS.01\u2013RTS,S\/AS01 heterologous prime boost vaccine efficacy against sporozoite challenge in healthy malaria-na\u00efve adults","volume":"10","author":"Ockenhouse","year":"2015","journal-title":"PLoS One"},{"key":"2025092306181873600_jiaf274-B4","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1093\/infdis\/jiw237","article-title":"Fractional third and fourth dose of RTS,S\/AS01 malaria candidate vaccine: a phase 2a controlled human malaria parasite infection and immunogenicity study","volume":"214","author":"Regules","year":"2016","journal-title":"J Infect Dis"},{"key":"2025092306181873600_jiaf274-B5","doi-asserted-by":"crossref","first-page":"e6465","DOI":"10.1371\/journal.pone.0006465","article-title":"Evaluation of RTS,S\/AS02A and RTS,S\/AS01B in adults in a high malaria transmission area","volume":"4","author":"Polhemus","year":"2009","journal-title":"PLoS One"},{"key":"2025092306181873600_jiaf274-B6","doi-asserted-by":"crossref","first-page":"249","DOI":"10.3389\/fmicb.2014.00249","article-title":"Malaria drives T cells to exhaustion","volume":"5","author":"Wykes","year":"2014","journal-title":"Front Microbiol"},{"key":"2025092306181873600_jiaf274-B7","doi-asserted-by":"crossref","first-page":"e1000912","DOI":"10.1371\/journal.ppat.1000912","article-title":"The Plasmodium falciparum-specific human memory B cell compartment expands gradually with repeated malaria infections","volume":"6","author":"Weiss","year":"2010","journal-title":"PLoS Pathog"},{"key":"2025092306181873600_jiaf274-B8","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.4049\/jimmunol.0901297","article-title":"Atypical memory B cells are greatly expanded in individuals living in a malaria-endemic area","volume":"183","author":"Weiss","year":"2009","journal-title":"J Immunol"},{"key":"2025092306181873600_jiaf274-B9","doi-asserted-by":"crossref","first-page":"3193","DOI":"10.1016\/j.celrep.2016.11.060","article-title":"Blood stage malaria disrupts humoral immunity to the pre-erythrocytic stage circumsporozoite protein","volume":"17","author":"Keitany","year":"2016","journal-title":"Cell Rep"},{"key":"2025092306181873600_jiaf274-B10","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.4049\/jimmunol.1202438","article-title":"Chronic exposure to Plasmodium falciparum is associated with phenotypic evidence of B and T cell exhaustion","volume":"190","author":"Illingworth","year":"2013","journal-title":"J Immunol"},{"key":"2025092306181873600_jiaf274-B11","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/ni.2211","article-title":"A new therapeutic strategy for malaria: targeting T cell exhaustion","volume":"13","author":"Freeman","year":"2012","journal-title":"Nat Immunol"},{"key":"2025092306181873600_jiaf274-B12","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1038\/ni.2180","article-title":"Therapeutic blockade of PD-L1 and LAG-3 rapidly clears established blood-stage Plasmodium infection","volume":"13","author":"Butler","year":"2012","journal-title":"Nat Immunol"},{"key":"2025092306181873600_jiaf274-B13","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1093\/infdis\/jiaa421","article-title":"A phase IIa controlled human malaria infection and immunogenicity study of RTS,S\/AS01E and RTS,S\/AS01B delayed fractional dose regimens in malaria-naive adults","volume":"222","author":"Moon","year":"2020","journal-title":"J Infect Dis"},{"key":"2025092306181873600_jiaf274-B14","doi-asserted-by":"crossref","first-page":"6398","DOI":"10.1016\/j.vaccine.2021.09.024","article-title":"A phase IIA extension study evaluating the effect of booster vaccination with a fractional dose of RTS,S\/AS01E in a controlled human malaria infection challenge","volume":"39","author":"Moon","year":"2021","journal-title":"Vaccine"},{"key":"2025092306181873600_jiaf274-B15","doi-asserted-by":"crossref","first-page":"2946","DOI":"10.1128\/JCM.00276-11","article-title":"Development of a highly sensitive genus-specific quantitative reverse transcriptase real-time PCR assay for detection and quantitation of Plasmodium by amplifying RNA and DNA of the 18S rRNA genes","volume":"49","author":"Kamau","year":"2011","journal-title":"J Clin Microbiol"},{"key":"2025092306181873600_jiaf274-B16","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1093\/cid\/ciac527","article-title":"Malaria transmission dynamics in a high-transmission setting of western Kenya and the inadequate treatment response to artemether-lumefantrine in an asymptomatic population","volume":"76","author":"Andagalu","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2025092306181873600_jiaf274-B17","author":"International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use Expert Working Group"},{"key":"2025092306181873600_jiaf274-B18","author":"International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use Expert Working Group"},{"key":"2025092306181873600_jiaf274-B19","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1056\/NEJMoa2026330","article-title":"Seasonal malaria vaccination with or without seasonal malaria chemoprevention","volume":"385","author":"Chandramohan","year":"2021","journal-title":"N Engl J Med"},{"key":"2025092306181873600_jiaf274-B20","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S1473-3099(23)00368-7","article-title":"Seasonal vaccination with RTS,S\/AS01E vaccine with or without seasonal malaria chemoprevention in children up to the age of 5 years in Burkina Faso and Mali: a double-blind, randomised, controlled, phase 3 trial","volume":"24","author":"Dicko","year":"2024","journal-title":"Lancet Infect Dis"},{"key":"2025092306181873600_jiaf274-B21","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1016\/S1473-3099(24)00360-8","article-title":"Safety and efficacy of PfSPZ vaccine against malaria in healthy adults and women anticipating pregnancy in Mali: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials","volume":"24","author":"Diawara","year":"2024","journal-title":"Lancet Infect Dis"},{"key":"2025092306181873600_jiaf274-B22","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/S1473-3099(24)00179-8","article-title":"Genotypic analysis of RTS,S\/AS01E malaria vaccine efficacy against parasite infection as a function of dosage regimen and baseline malaria infection status in children aged 5\u201317 months in Ghana and Kenya: a longitudinal phase 2b randomised controlled trial","volume":"24","author":"Juraska","year":"2024","journal-title":"Lancet Infect Dis"},{"key":"2025092306181873600_jiaf274-B23","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1086\/600120","article-title":"Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS,S\/AS01B and RTS,S\/AS02A in malaria-naive adults: safety, efficacy, and immunologic associates of protection","volume":"200","author":"Kester","year":"2009","journal-title":"J Infect Dis"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jid\/advance-article-pdf\/doi\/10.1093\/infdis\/jiaf274\/63385617\/jiaf274.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/232\/3\/e372\/63385617\/jiaf274.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/232\/3\/e372\/63385617\/jiaf274.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T10:27:33Z","timestamp":1758623253000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/232\/3\/e372\/8151891"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,29]]},"references-count":23,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,5,29]]},"published-print":{"date-parts":[[2025,9,15]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiaf274","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,9,15]]},"published":{"date-parts":[[2025,5,29]]}}}